Evidence map›Paper›PMID 42086599›Full record

ArticleNPJ vaccines2026

Monovalent and multivalent OspA mRNA-LNP vaccines elicit functional antibodies and protect against Borrelia burgdorferi in mice.

Meredith B Finn, Graham Willsey, Carol Lyn Piazza, Luke Clendenen, Muskan Shrestha, Stephanie Soee You, Lingzhi Ma, Yukti Dhingra, Adrian R Laciak, Kevin A Uggowitzer and 12 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05975099 (A Phase 1/2, Randomized, Observer-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Immunogenicity of Heptavalent mRNA-1975), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05975099 phase1 / phase2completednot on this map

A Phase 1/2, Randomized, Observer-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Immunogenicity of Heptavalent mRNA-1975 (SR1-7) and Monovalent mRNA-1982 (SR1) in Parallel Against Lyme Disease in Healthy Participants 18 Through 70 Years of Age

TypeinterventionalSponsorModernaTX, Inc.Ran2023 to 2025Enrolled807ConditionsLyme DiseaseArmsmRNA-1975, mRNA-1982, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Meredith B FinnInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA.
Graham WillseyDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Carol Lyn PiazzaDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Luke ClendenenDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.
Muskan ShresthaDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.
Stephanie Soee YouDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.
Lingzhi MaInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA.
Yukti DhingraInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA.
Adrian R LaciakInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA.
Kevin A UggowitzerInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA.
Joshua M ObieroInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA.
Grace Freeman-GallantDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Harini NatarajanInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA.
Shannon GreenInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA.
Elham PirayeshInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA.
Yen-Ting LaiInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA.
Sunny HimansuInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA.
Andrea CarfiInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA.
Linden T HuDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.
Nicholas MantisDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Obadiah PlanteInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA.
Christina DoldInfectious Disease Research, Moderna, Inc., Cambridge, MA, USA. Christina.Dold@modernatx.com.

Funding

Tickborne Disease: B cell epitope discovery and mechanisms of antibody Protection75N93019C00040 · NIAID · NYSDOH/HEALTH RESEARCH, INC. · PI MANTIS, NICHOLAS J. · 2019 to 2023
$10.3M
NIH HHS 75N93019C00040
6 · The paper itself

Abstract

Outer surface protein A (OspA) is a ~30 kDa lipoprotein displayed on the surface of Borrelia burgdorferi sensu lato, the etiological agent of Lyme disease. Here we report on the preclinical evaluation of OspA-encoding nucleoside-modified mRNA lipid nanoparticle (OspA mRNA-LNP) vaccines for the prevention of Lyme disease. Crystallographic and binding studies using a panel of transmission-blocking antibodies confirmed that the mRNA-encoded OspA serotype 1 (ST1) expressed in mammalian cells assumes its native structure and retains known protective epitopes. Immunization of mice with OspA ST1 mRNA-LNP elicited functional serum antibodies that promoted spirochete agglutination and complement-dependent borreliacidal activity in vitro. We also examined the impact of combining ST1 OspA mRNA with OspA STs 2-7, which are associated with predominant Borrelia genospecies in Europe (B. garinii, B. afzelii, and B. bavariensis). The additional six STs mRNA did not interfere with ST1 antibody titers and functionality. Finally, mice vaccinated two or three times with different dose levels of OspA ST1 mRNA-LNP or with the heptavalent mRNA vaccine were protected against B. burgdorferi infection in a tick-mediated challenge model. The monovalent and the heptavalent OspA mRNA vaccines (mRNA-1982 and mRNA-1975, respectively) are currently undergoing testing in a Phase 1 clinical trial (NCT05975099).

Identifiers

PMID42086599
PMCPMC13478462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.